Nestlé is using artificial intelligence to create specialized nutrition products for consumers on GLP-1 weight-loss drugs. This strategy aims to tackle side effects like muscle loss and capture a new market segment. As the global food giant faces profit pressures, investors are watching whether this shift can offset changing consumption habits caused by appetite-suppressing medications.
Nestlé is deploying artificial intelligence and advanced nutritional science to develop a new line of food and supplement products designed for consumers taking GLP-1 weight-loss drugs, such as Ozempic and Mounjaro. By targeting the specific health needs of this growing user base, the company is attempting to turn a potential threat to its traditional business into a new revenue opportunity.
The Strategic Pivot
Millions of people globally are using GLP-1 medications to manage weight. These drugs often suppress appetite, which has raised concerns among investors that consumers may buy fewer traditional packaged food products, such as snacks and confectionery—core categories for many food companies. Instead of viewing this shift as a purely negative trend, Nestlé is aiming to capture the demand for health-conscious, nutrient-dense alternatives. The company has already launched its 'Vital Pursuit' brand in the U.S., which focuses on high-protein, portion-aligned meals, and has introduced high-protein variants of existing products like its Milo malt drink.
AI-Powered Product Development
To speed up the creation of these specialized products, Nestlé is using an internal AI platform named 'Food Genie.' This tool helps the company's research team analyze thousands of clinical studies and recipes to find the right nutrient combinations. The primary goal is to address side effects commonly reported by GLP-1 users, such as muscle mass depletion and nutritional deficiencies. By using AI to simulate consumer preferences and predict recipe performance, the company hopes to bring health-focused products to market faster and more efficiently.
Financial Context and Market Challenges
This shift comes at a time when the parent company, Nestlé, is navigating significant financial headwinds. In the first half of 2026, the company reported an organic growth of 3.6%, but its global net profit fell by 31.4% to CHF 3.5 billion. This decline reflects a difficult operating environment characterized by high input costs, margin pressures, and volatile foreign exchange rates. Investors are monitoring whether the company's focus on high-value, specialized nutrition can help recover margins and offset the impact of inflationary pressures.
Potential Risks and Market Reception
While the strategy seeks to address a clear consumer need, it is not without risks. Some nutrition experts remain skeptical, arguing that whole, natural foods such as meat, fish, eggs, and vegetables offer similar nutritional benefits at a lower cost compared to processed specialized supplements. Furthermore, the success of this product line depends on whether consumers view these items as essential or as an unnecessary expense. The company must also manage the global macroeconomic risks that have recently impacted its profitability. For shareholders, the next key monitorable will be the sales performance of these new health-focused products and whether they can effectively compensate for any decline in demand for the company’s traditional snack portfolio.